https://www.live-feeds.com/feed/the-race-to-develop-more-medicines-like-the-new-pancreatic-cancer-drugContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/the-race-to-develop-more-medicines-like-the-new-pancreatic-cancer-drughttps://www.live-feeds.com/feed/the-race-to-develop-more-medicines-like-the-new-pancreatic-cancer-drug#u54699Wed, 02 Sep 2026 10:05:15 +0000The FDA approved Rasonque (daraxonrasib), an oral multi-selective RAS(ON) inhibitor for adults with metastatic pancreatic adenocarcinoma who failed or are ineligible for one prior systemic therapy. Developed by Revolution Medicines, the drug doubled median survival rates in the RASolute 302 trial. University of Cincinnati researchers contributed the foundational work for the treatment, which targeted a gene previously considered undruggable. Early-stage data published in Nature Communications suggests combining such therapies could help patients overcome immunotherapy resistance, with one indi https://www.live-feeds.com/feed/the-race-to-develop-more-medicines-like-the-new-pancreatic-cancer-drughttps://www.live-feeds.com/feed/the-race-to-develop-more-medicines-like-the-new-pancreatic-cancer-drug#u51774Sat, 29 Aug 2026 12:55:07 +0000The FDA approved Rasonque (daraxonrasib), an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who are ineligible for or have failed one prior systemic therapy. Developed by Revolution Medicines, the drug doubled median survival rates in the RASolute 302 trial. The approval occurred five weeks after the company filed using a national priority voucher. While Rasonque targets a previously undruggable gene, separate early-stage trial results published in Nature Communications suggest combination therapies may help patients overcome immunotherapy resistan https://www.live-feeds.com/feed/the-race-to-develop-more-medicines-like-the-new-pancreatic-cancer-drughttps://www.live-feeds.com/feed/the-race-to-develop-more-medicines-like-the-new-pancreatic-cancer-drug#u50534Fri, 28 Aug 2026 06:45:52 +0000The FDA approved RASONQUE (daraxonrasib) on August 26, 2026, as a once-daily oral pill for pancreatic cancer. The drug doubled median survival rates compared to chemotherapy. Experts suggest the treatment could transform care for a disease long considered intractable, as it targets a gene previously viewed as undruggable. Patients at institutions including Dartmouth are among the first to receive the medication.Why it mattersPancreatic cancer is one of the deadliest forms of the disease and has remained difficult to treat for decades. This approval follows long-term research efforts to find a